Poly Medicure Limited (NSE: POLYMED) announced on May 25, 2026, that its Board of Directors has recommended a final dividend of ₹3.50 per equity share for the financial year ended March 31, 2026. The announcement was made alongside the submission of audited standalone and consolidated financial results for Q4 and full-year FY2026 to the exchanges.

Dividend Details

The recommended final dividend of ₹3.50 per share marks a 16.7% increase over the ₹3.00 per share paid in FY2024, which was the last declared dividend prior to this announcement. The dividend is subject to shareholder approval at the upcoming Annual General Meeting. The face value of POLYMED shares is ₹5 per equity share, making the dividend equivalent to 70% of face value.

Dividend History and Growth Trend

Poly Medicure has maintained an uninterrupted dividend payout track record over the past decade. The per-share dividend history reflects a clear upward trajectory:

Over the past nine years, the per-share dividend has grown sevenfold from ₹0.50 in FY2017 to ₹3.50 in FY2026, reflecting the company's consistent improvement in cash generation and its commitment to rewarding shareholders progressively.

Market Context and Dividend Yield

Poly Medicure's stock quote data was not available at the time of this report. For reference, the company's 52-week price range on NSE has reflected significant valuation expansion in line with broader medical devices sector re-rating. Investors should compute the current dividend yield by dividing the ₹3.50 per share payout by the prevailing market price. At a hypothetical price of ₹1,000 per share, the yield would stand at approximately 0.35%, which is typical for growth-oriented medical devices companies where capital appreciation rather than income distribution remains the primary return driver. Investors are advised to check the latest traded price on NSE for an accurate yield calculation.

Company Background

Poly Medicure Limited is a Faridabad-based manufacturer of single-use medical devices, supplying products such as IV sets, catheters, blood transfusion sets, and surgical disposables. The company exports to over 100 countries and derives a significant share of revenues from international markets, particularly Europe, the United States, and the Middle East. It is one of the few SEBI-listed pure-play medical disposables manufacturers in India.

What This Means for Investors

The 16.7% increase in the final dividend signals management's confidence in the company's cash flow position following FY2026. For long-term shareholders who acquired the stock at lower historical prices, the effective yield on cost is meaningfully higher than the current-price yield. The consistent dividend growth over nine years, combined with no dividend cut even during the FY2020 period, reinforces the company's financial stability. Shareholders should watch for the record date announcement, which will determine eligibility for the ₹3.50 per share payout, and monitor the audited FY2026 financial results filed alongside this announcement for revenue and profitability details.